Is Dapagliflozin propylene glycol hydrate Safe in Breastfeeding

I am a breastfeeding mother and i want to know if it is safe to use Dapagliflozin propylene glycol hydrate? Is Dapagliflozin propylene glycol hydrate safe for nursing mother and child? Does Dapagliflozin propylene glycol hydrate extracts into breast milk? Does Dapagliflozin propylene glycol hydrate has any long term or short term side effects on infants? Can Dapagliflozin propylene glycol hydrate influence milk supply or can Dapagliflozin propylene glycol hydrate decrease milk supply in lactating mothers?

• DrLact safety Score for Dapagliflozin propylene glycol hydrate is 5 out of 8 which is considered Unsafe as per our analyses.
• A safety Score of 5 indicates that usage of Dapagliflozin propylene glycol hydrate may cause serious side effects in breastfed baby.
• Our study of different scientific research indicates that Dapagliflozin propylene glycol hydrate may cause moderate to high side effects or may affect milk supply in lactating mother.
• Our suggestion is to use safer alternate options rather than using Dapagliflozin propylene glycol hydrate .
• It is recommended to evaluate the advantage of not breastfeeding while using Dapagliflozin propylene glycol hydrate Vs not using Dapagliflozin propylene glycol hydrate And continue breastfeeding.
• While using Dapagliflozin propylene glycol hydrate Its must to monitor child for possible reactions. It is also important to understand that side effects vary largely based on age of breastfed child and time of medication in addition to dosage.
• Score calculated using the DrLact safety Version 1.2 model, this score ranges from 0 to 8 and measures overall safety of drug in lactation. Scores are primarily calculated using publicly available case studies, research papers, other scientific journals and publically available data.

Dapagliflozin is a selective and reversible inhibitor of the sodium and glucose co-transporter 2 (SGLT2). It acts by reducing the renal reabsorption of glucose and increasing its elimination via urine (Kasichayanula 2014, Plosker 2014).Administered orally once a day. Low risk of hypoglycemia in monotherapy, which increases when it is associated with other hypoglycaemic agents (EMA 2017, Plosker 2014). Since the last update, we have not found published data on its excretion in breast milk. Its high percentage of protein binding (EMA 2017) makes its transfer to milk in significant quantities unlikely, but the low molecular weight and its elimination half-life greater than 12 hours could facilitate a possible transfer. Until there is more published data on this drug in relation to breastfeeding, safer known alternatives may be preferable, especially during the neonatal period and in case of prematurity. Diet, exercise and breastfeeding improve blood glucose levels.